Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows

The fear of testosterone and prostate cancer traces back to a single experiment published in 1941, and understanding why that experiment was misread requires first understanding how testosterone actually reaches and affects the prostate.

Testosterone travels through the bloodstream and binds to something called androgen receptors, which are proteins inside prostate cells that act like locks waiting for a key. When testosterone binds to those receptors, the cell gets a signal to grow and function. The assumption in 1941, and for decades after, was that more testosterone means more receptor activation means more growth, and that a cancer-prone prostate would just keep growing with every extra nanogram you threw at it.

That assumption turned out to be wrong, but it won a Nobel Prize first.

Charles Huggins published his findings in 1941 showing that castrating men with advanced metastatic prostate cancer reduced their acid phosphatase, which was a marker of prostate cancer activity, and that injecting testosterone back into those castrated men drove the marker back up. The medical community read this and concluded that testosterone feeds prostate cancer, that removing it starves the cancer, and that adding it back is dangerous.

What they missed is that those were castrated men, meaning their testosterone was functionally zero, and the effect of testosterone at near-zero levels is completely different from the effect at normal physiological levels.

This is where something called the saturation model becomes the turning point. Androgen receptors inside prostate tissue have a finite number of binding sites, and once those sites are fully occupied, adding more testosterone does nothing because there are no empty locks left for the key to open. Research by Morgentaler and Traish published in 2009 identified that saturation point at roughly 240 to 250 nanograms per deciliter of testosterone in the blood.

Below that threshold, changes in testosterone have dramatic effects on prostate tissue because you are going from few receptors filled to many. Above that threshold, the response flatlines because the receptors are already saturated. A man doing TRT typically targets somewhere between 500 and 900 nanograms per deciliter, which means he is operating entirely above the saturation zone and his prostate is simply not responding to marginal changes in testosterone the way Huggins' castrated patients were.

The 1941 experiment was real. The castration finding was real. The error was in generalizing from zero to normal, as if every additional unit of testosterone would keep producing the same proportional response forever.

So what happened when researchers actually followed men on TRT and looked at prostate cancer rates?

The largest randomized controlled trial to examine this directly enrolled 5,204 men and followed them for an average of 33 months. Prostate cancer developed in 0.46 percent of men on TRT and 0.42 percent on placebo, and the hazard ratio was 1.07 with a p-value of 0.87, meaning statistically there was no difference at all. A Finnish population study following 78,615 men over 18 years found that TRT users actually had lower prostate cancer-specific mortality, with a hazard ratio of 0.52 compared to non-users. A 2024 meta-analysis pulling together 28 randomized controlled trials found that PSA, which is a blood marker for prostate activity, changed by an average of 0.08 nanograms per milliliter in TRT users compared to controls, and that the international prostate symptom score changed by exactly zero.

Those numbers do not suggest a therapy that is silently causing prostate cancer.

The hardest version of the question is not about healthy men though. It is about men who already have prostate cancer. If testosterone feeds prostate cancer, then giving TRT to a man who has already been treated for prostate cancer should make it come back. Researchers looked at exactly this group, 69,984 men who had undergone definitive treatment for localized prostate cancer, and 1,012 of them received TRT afterward. There was no increase in recurrence and no increase in death from prostate cancer. If testosterone does not accelerate existing cancer in men who have already had it, the argument that it causes cancer in men who do not have it becomes very difficult to sustain.

The practical implication of all this is not that you ignore your prostate when starting TRT. It is that the monitoring matters but the fear does not have to.

Before starting TRT, get a baseline PSA test. This is a simple blood draw that gives you a reference point so any future change can be measured against something real rather than in a vacuum. Check it again at three to six months after starting, and then annually from there. The Endocrine Society guideline flags a rise of more than 1.4 nanograms per milliliter above your personal baseline as a threshold to refer to urology for further evaluation. That number is not about panic, it is about having a tripwire that triggers appropriate attention rather than either ignoring everything or being afraid of everything.

The saturation model reframes the entire conversation. Men with hypogonadism, meaning low testosterone, are actually operating closer to the zone where testosterone fluctuations matter to prostate tissue, and bringing them up to normal levels moves them further away from that sensitive zone rather than into danger.

Eighty years of clinical fear condensed down to this: the original experiment was done in castrated men with metastatic cancer, and the conclusion was extrapolated to healthy men on replacement therapy, which is a different physiology, a different starting point, and a different relationship to the saturation threshold entirely. The data collected since then has consistently failed to find the harm that the 1941 logic predicted, and the mechanism explaining why it would not cause harm has been worked out in detail.

The fear was not irrational given what was known in 1941. It just never got updated.

---

References

1. Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
2. Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
3. Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
4. Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
5. Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
6. Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
7. Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness